Centers for Medicare & Medi-Cal Part D Drug Cost Negotiations:

What to Expect in 2026 for your Part D Drug Costs

(CMS) has taken decisive action to negotiate prices for ten specific Medicare Part D drugs. This marks a significant milestone as these are the first drugs to be negotiated under the Inflation Reduction Act.

The selected drugs for 2026 include treatments for several conditions: 

• Diabetes: Januvia, Jardiance, Farxiga, Fiasp/NovoLog

• Blood clots: Eliquis, Xarelto

• Heart failure: Entresto, Farxiga

• Psoriasis and Crohn's disease: Stelara

• Rheumatoid Arthritis: Enbrel

• Blood cancers: Imbruvica 

These drugs have been strategically selected based on the criteria established by the Inflation Reduction Act. They are among the top-spending medications that lack generic or biosimilar competition and meet specific age requirements since their FDA approval.

Projected Savings for People with Medicare Part D Coverage:

Starting in January 1, 2026, when the negotiated prices are implemented, individuals enrolled in Medicare prescription drug coverage will benefit from an estimated $1.5 billion in savings under the projected standard benefit design. These substantial savings from the Negotiation Program will further enhance the impactful cost-saving provisions of the Inflation Reduction Act, including the groundbreaking cap on out-of-pocket drug costs for Medicare beneficiaries.

Stay tuned for further updates!

*Source CMS.gov